SMPL
New Delhi [India], September 11: CliniExperts Research Services is proud to announce its contribution to the RAAINBOW Phase 2/3 global clinical trial, evaluating Cinainu, the world's first botanical topical drug-candidate for the treatment of moderate to severe paediatric Alopecia Areata (AA). The groundbreaking results have been published in the British Journal of Dermatology, on 16th of July, 2025.
CliniExperts Research Services played a key role in conducting the India arm of the trial, managing clinical operations across multiple sites, data analysis, and reporting, in collaboration with Legacy Healthcare, the Switzerland-based biopharmaceutical company leading the trial.
About Paediatric Alopecia Areata & Cinainu
Alopecia Areata (AA) is an autoimmune disorder causing patchy hair loss, with limited safe treatment options for children. Cinainu is a patented botanical topical solution targeting inflammation, apoptosis, and oxidative stress in AA physiology.
About the RAAINBOW Trial
* multinational, randomized, double-blind, placebo-controlled, multicentric Phase 2/3 trial in paediatric AA.
* Conducted across 12 sites in 4 countries with 107 patients aged 2-18 years
* India's contribution: Led by CliniExperts Research Services, which ensured compliance with safety, regulatory, and quality standards, while delivering comprehensive data analysis.